Terns Pharmaceuticals, Inc. (TERN) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Foster City, CA, United States. El CEO actual es Melita Sun Jung.
TERN tiene fecha de IPO 2021-02-05, 59 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $4.75B.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes TERN-101, a farnesoid X receptor agonist in Phase IIa trials for NASH; TERN-201, a vascular adhesion protein-1 inhibitor in Phase Ib development; TERN-501, a thyroid hormone receptor beta agonist in Phase I trials; and TERN-601, an oral Glucagon-Like Peptide-1 receptor agonist program targeting NASH and metabolic diseases. Founded in 2016 and headquartered in Foster City, California, Terns is advancing both single-agent and combination therapy candidates to address significant unmet medical needs in metabolic disease treatment.
